Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. RTB
6. ONON
7. AAPL
8. TRMD
9. AZN
10. SPCX

Go back to Karyopharm Therapeutics (KPTI) Announces Proposed $150M Public Offering of Common Stock

Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock

March 2, 2020 4:01 PM EST

NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to $22.5 million in shares of its common stock.

J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.

An automatically effective shelf registration statement relating to the shares of common... More

Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy

March 2, 2020 7:00 AM EST

Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone (Vd) Regimen  

47% Increase in Median PFS on SVd versus Vd

Regulatory Submission Planned in 2Q 2020; Data to be Submitted for Presentation at Upcoming Medical Meetings

Management to Host Conference Call Today at 8:30 AM ET

NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today... More